Unanswered Inquiries Into Poziotinib Revealed

[23] They concluded that mortality risks started to increase significantly at BMI ��25.0?kg/m2 rather than at BMI ��30.0?kg/m2 in the Asian population, and supported the use of BMI ��25?kg/m2 as a new cut-off point for obesity in Asians and a BMI of 23.0�C24.9?kg/m2 for classification of Asian people as overweight. Recent Asia�CPacific Cohort Studies[24] indicated that PCa mortality started to increase at a BMI ��25.0?kg/m2. The aforementioned findings might be compatible with the present finding that a high-grade disease risk starts to increase at a BMI ��25?kg/m2. Age, serum PSA and PV have been reported to potentially obscure the impact of BMI on PCa risk at biopsy.[25, 26] In the current study, age had a negative association http://www.selleckchem.com/products/poziotinib-hm781-36b.html with BMI. This finding is compatible with the National Nutrition Survey of Japan 1956�C2005, which reported that the BMI in men increased with age by birth cohort, but decreased with cross-sectional age.[27] After adjusting http://www.selleckchem.com/products/ganetespib-sta-9090.html for age, the significantly elevated PCa risk in men with a low BMI ( http://www.selleck.cn/products/cobimetinib-gdc-0973-rg7420.html Korean men, who are generally similar to Japanese men in BMI distribution, and who underwent extended biopsy; these results included high-grade disease.13 The results from a previous Japanese research paper, however, are consistent with the present results.12 The reason for this discrepancy between the Korean and Japanese studies remains unknown. Additional research involving another large-cohort study in Asia seems to be required to resolve the ambiguity. Several limitations should be considered when interpreting our data.